Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat

• LIPO-202 (Drug), also known as Salmeterol
• Placebo (Drug), also known as Placebo for LIPO-202

Primary outcomes

• Safety as measured by Physical examination, adverse events, vital signs, and laboratory tests. [8 weeks]: Physical examination, adverse events, vital signs, and laboratory tests.
• Change in the clinician reported photonumeric score [8 weeks post the start of treatment]
• Change in the patient reported global abdominal perception score [8 weeks post the start of treatment]

Secondary outcomes

• Change in waist circumference [8 weeks post the start of treatment]

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Healthy male or non-pregnant female subjects
* Capable of providing written consent.
* BMI < 30 kg/m2
* Stable diet and exercise routine
* Central abdominal bulging that is evaluated by the clinician at least slight bulge, not flat

Exclusion Criteria:

* Have had any treatment of the fat around your abdomen, including surgical procedures (tummy tuck, liposuction), injections for fat loss or treatments with devices to reduce fat in your abdomen.
* Plan on starting a weight loss or exercise program during the study.
* Known hypersensitivity to study drugs

• Maria Feldman, Study director, Neothetics, Inc